Orzeyful Reaches Patients After DEA Places Narcolepsy Drug in Schedule IV

Orzeyful (oveporexton), Takeda's narcolepsy pill, is now available by prescription in the United States. The Drug Enforcement Administration published an interim final rule on November 12, 2026, placing oveporexton in Schedule IV of the Controlled Substances Act, and Takeda launched the drug the same day. The Food and Drug Administration had approved it on August 5, 2026, for narcolepsy type 1 in adults, but a drug the FDA says should be controlled can't be sold until the DEA schedules it.

Narcolepsy type 1 is caused by the loss of brain cells that produce orexin, a chemical that helps the brain hold wakefulness. Its symptoms include excessive daytime sleepiness and cataplexy, a sudden loss of muscle tone triggered by emotion. Orzeyful is an oral orexin receptor 2 agonist. It stimulates the receptor the missing orexin would have reached, which makes it the first approved drug in its class and the first treatment aimed at the deficiency itself rather than at the sleepiness downstream of it.

The scheduling followed the path Congress built for newly approved medicines. The Department of Health and Human Services sent the DEA its scientific and medical evaluation and a Schedule IV recommendation on July 31, 2026. In the human abuse-potential study behind that recommendation, high doses of oveporexton produced drug-liking scores not statistically different from phentermine, a Schedule IV stimulant, and the agencies concluded the drug carries a low risk of physical or psychological dependence. The rule, Docket No. DEA-1775, took effect on publication. Comments are open for 30 days after publication, through December 14, 2026.

Schedule IV is a lighter rung than the one under the field's established drugs. Oxybate-based treatments such as Xyrem, Xywav and Lumryz sit in Schedule III, and the stimulants many patients use sit higher still. Placement doesn't change what Orzeyful does in the body. It changes the handling around the prescription: the refill rules, the monitoring paperwork and the pharmacy channel a patient has to use.

That channel is narrow at launch. Orzeyful is dispensed through Accredo, the specialty pharmacy run by Evernorth Health Services, Cigna's health services arm. The U.S. list price is $16,500 per 60-tablet bottle, the same across all strengths. The drug is taken twice daily, so a bottle is a month's supply, and the annual list figure lands near $198,000 before any discount, rebate or coverage decision touches it.

The approval rests on two 12-week Phase 3 trials, First Light and Radiant Light, which together enrolled 273 adults with narcolepsy type 1. For patients, the practical news is simpler than the regulatory path that produced it. A first-in-class drug that sat approved but unsellable for three months can now be prescribed, and the first prescriptions move through one specialty pharmacy at a five-figure monthly list price.

The DEA acted under a fast-track Congress wrote for cases exactly like this one. When the health department recommends controlling a newly approved drug in Schedules II through V, the statute at 21 U.S.C. 811(j) directs the DEA to issue an interim final rule on a 90-day clock instead of running a full propose-and-comment cycle first. HHS sent its recommendation on July 31, 2026. The rule landed November 12, inside the window, with the comment period running after the scheduling took effect rather than before it.

The trial record behind the approval is published. Results from First Light and Radiant Light appeared in The New England Journal of Medicine in September 2026. Schedule IV handling is the part patients will actually feel. Federal rules let Schedule IV prescriptions be refilled up to five times within six months, a lighter regime than the one governing the Schedule III oxybates, which is one reason analysts read the placement as a commercial advantage for Takeda. None of that changes the specialty pharmacy gate at launch, or the $16,500 list price standing behind it.